Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

References

• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1–9.
   PubMed Web of Science ®Google Scholar
• Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther. 2021;11(3):1053–1064.
   Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–1179.
   PubMed Web of Science ®Google Scholar
• Liu J, Thatiparthi A, Martin A, et al. Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 national health and nutrition examination surveys. J Am Acad Dermatol. 2021;84(3):767–769.
   PubMed Web of Science ®Google Scholar
• Levin EC, Gupta R, Brown G, et al. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014;25(1):78–82.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256–2269.
   PubMed Web of Science ®Google Scholar
• Carrascosa J-M, Garcia-Doval I, Pérez-Zafrilla B, et al. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26(6):502–506.
   PubMed Web of Science ®Google Scholar
• Esposito M, Gisondi P, Conti A, et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31(5):863–869.
   PubMed Web of Science ®Google Scholar
• Gambardella A, Licata G, Sohrt A. Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review. Dermatol Ther. 2021;11(4):1141–1156.
   Web of Science ®Google Scholar
• Pinter A, et al. Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan P1606 Poster presented at: European Academy of Dermatology and Venereology Congress; September 2022, Milan, Italy.
   Google Scholar
• Bagel J, Glick B, Wu JJ, et al. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data. J Med Econ. 2021;24(1):782–791.
   PubMed Web of Science ®Google Scholar
• Iskandar I, Ashcroft D, Warren R, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2017;176(5):1297–1307.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Leonardi C, Gordon K, et al. Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;32(8):1297–1304.
   PubMed Web of Science ®Google Scholar
• van den Reek JM, van Lümig PP, Kievit W, et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat. 2013;24(5):361–368.
   PubMed Web of Science ®Google Scholar
• AbbVie. AbbVie expands immunology portfolio in the U.S. with FDA approval of SKYRIZI™ (risankizumab-rzaa) for moderate to severe plaque psoriasis. [PressRelease]. 2019. [cited 2022 Mar 25]. https://news.abbvie.com/news/press-releases/abbvie-expands-immunology-portfolio-in-us-with-fda-approval-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis.htm.
   Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658.
   PubMed Web of Science ®Google Scholar
• Papp KA, Lebwohl MG, Puig L, et al. Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up. Br J Dermatol. 2021;185(6):1135–1145.
   PubMed Web of Science ®Google Scholar
• Ehrenberg R, Griffith J, Theigs C, et al. Dose escalation assessment among targeted immunomodulators in the management of inflammatory bowel disease. J Manag Care Spec Pharm. 2020;26(6):758–765.
   PubMed Web of Science ®Google Scholar
• Cosentyx (secukinumab) injection, for subcutaneous use. Novartis. January 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf. Accessed on October 10, 2022.
   Google Scholar
• Taltz (ixekizumab) injection, for subcutaneous use. Eli Lilly. March 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf. Accessed on October 10, 2022.
   Google Scholar
• Siliq (brodalumab) injection, for subcutaneous use. Valeant Pharmaceuticals. February 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf. Accessed on October 10, 2022.
   Google Scholar
• Tremfya (guselkumab) injections, for subcutaneous use. Janssen Biotech. July 2020. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed on October 10, 2022.
   Google Scholar
• Ilumya (tildrakizumab-asmn) injection, for subcutaneous use. Sun Pharma. March 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed on October 10, 2022.
   Google Scholar
• Skyrizi (risankizumab-rzaa) injection, for subcutaneous use. AbbVie. April 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf. Accessed on October 10, 2022.
   Google Scholar
• Humira (adalimumab) injection, for subcutaneous use. AbbVie. February 2021. https://www.rxabbvie.com/pdf/humira.pdf. Accessed on October 10, 2022.
   Google Scholar
• Stelara (ustekinumab) injection, for subcutaneous or intravenous use. Janssen Biotech. August 2022. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed on October 10, 2022.
   Google Scholar
• Cimzia (certolizumab pegol) for injection, for subcutaneous use. UCB. September 2019. https://www.cimzia.com/themes/custom/cimzia/docs/CIMZIA_full_prescribing_information.pdf. Accessed on October 10, 2022.
   Google Scholar
• Enbrel (etanercept) injection, for subcutaneous use. Pfizer. December 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf. Accessed on October 10, 2022.
   Google Scholar
• Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201–209.
   PubMedGoogle Scholar
• Armstrong A, Jarvis S, Boehncke W-H, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the clear about psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200–2207.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis. JAMA Dermatol. 2020;156(3):258–269.
   PubMed Web of Science ®Google Scholar
• Haidari W, Pona A, Feldman SR. Management of residual psoriasis in patients on biologic treatment. J Drugs Dermatol. 2020;19(2):188–194.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Zhou H, et al. Economic impact of above-label dosing with etanercept, adalimumab, or ustekinumab in patients with psoriasis. J Manag Care Spec Pharm. 2017;23(5):583–589.
   PubMedGoogle Scholar
• AbbVie (2022). Durable efficacy in psoriasis achieved by SKYRIZI patients through to 4.5 years. https://www.abbviepro.com/gb/en/immunology/dermatology/products/skyrizi/efficacy.html. Accessed on August 25, 2022.
   Google Scholar